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1. Introduction
Hepatitis B is an important public health issue 
in South Africa (SA). Prior to the introduction 
of the hepatitis B vaccine into the South African 
Expanded Programme of Immunisation (EPI) in 
1995, prevalence rates of this disease were 0.3 - 15%.[1] 
However, unlike countries such as Taiwan,[2] SA has had no catch-up 
vaccination programme to ensure complete vaccination coverage. In 
addition, the HIV/AIDS pandemic has had a potentially deleterious 
influence on the natural history of patients co-infected with HIV and 
the hepatitis B virus (HBV).[3] 
The spectrum of disease and natural history of chronic HBV 
infection is diverse, ranging from a low viraemic immune control state 
to progressive chronic hepatitis, with the potential for the ensuing 
complications of cirrhosis, liver failure and hepatocellular carcinoma 
(HCC). [4] As understanding of the natural history of chronic hepatitis B 
increased over the past decade, there have been significant therapeutic 
advances. The decision to treat and the choice of therapy is dependent 
on both the phase of chronic infection and patient factors. 
This guideline draws on the recently published guidelines by 
the American Association for the Study of Liver Disease (AASLD), 
the European Association for the Study of the Liver (EASL), 
the Asia-Pacific Association for the Study of the Liver (APASL), 
National Institutes of Health (NIH) and the World Gastroenterology 
Organisation (WGO).[5-9] It serves as an attempt to contextualise 
practice guidelines on the management of chronic hepatitis B in SA.
2. Pathogenesis and natural history 
See Table 1. Hepatitis is an enveloped partially double-stranded 
DNA virus belonging to the Hepadnaviridae family. It is 100 times 
more infectious than HIV and can be transmitted by perinatal, 
percutaneous and sexual exposure.[10] Close person-to-person contact 
is an important form of transmission, most notably among children 
in highly endemic areas, such as in SA.[5,10]
Liver injury due to hepatitis B is mainly caused by cellular immune 
mediated mechanisms with cytotoxic T lymphocyte lysis of infected 
hepatocytes. The magnitude of the individual’s adaptive cellular 
immune response to HBV-related antigens determines the outcome of 
acute HBV infection, as well as the degree of liver injury. Chronically 
infected patients are unable to sustain an immune response to HBV 
and may experience intermittent episodes of hepatocyte destruction in 
an attempt to clear virally infected hepatocytes, in what can be termed 
‘flares’. Note that, during the acute infection, hepatitis B does not appear 
to induce an intra-hepatic innate immune response. Instead, it acts as a 
‘stealth’ virus early in the infection.[9]
Age is also an important host factor determining the risk of 
chronicity. Following acute exposure to HBV, 90% of neonates born 
to hepatitis B ‘e’ antigen (HBeAg)-positive mothers, 20 - 50% of 
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infants and children under the age of 5 years, and <5% of adults will 
develop chronic hepatitis B infection.[11,12] Viral variants may also 
influence the course and outcome of the disease. In addition, and 
only rarely and in the setting of profound immune suppression, the 
virus can be directly cytopathic. 
In choosing an appropriate management strategy, a clear 
understanding of the process of hepatitis B viral replication, as well 
as the natural history of chronic hepatitis B, is vital: 
Following acute exposure, the HBV enters the hepatocyte and is 
imported into the nucleus. The partially doubled-stranded DNA 
is repaired to form a circular extra-chromosomal molecule called 
the covalently closed circular DNA (cccDNA),[13] which is the 
transcriptional template for the viral messenger RNAs (mRNAs). The 
RNA form of the genome is encapsidated together with the reverse 
transcriptase, and reverse transcription occurs within the cytoplasm. 
Cytoplasmic viral capsids containing mature viral DNA are either 
transported to the nucleus, thereby replenishing cccDNA, or bind to 
HBV surface antigens which have accumulated in the endoplasmic 
reticulum, bud through the cellular membranes and are secreted 
from the hepatocyte non-cytopathically, as virions. 
Hence, even if the individual clears hepatitis B surface antigen 
(HBsAg), the hepatocyte still harbours cccDNA. This is the basis 
of occult HBV infection, which is defined as detectable HBV 
DNA in the liver and a very low level (<200 IU/ml) of HBV DNA 
in the blood of those previously exposed to HBV, viz. HBsAg 
negative and hepatitis B immunoglobulin G core antibody (anti-
HBc IgG) positive. The clinical significance of occult HBV is that 
immunosuppression may lead to reactivation in these patients. 
HBV DNA can also integrate into the cellular genome during 
chronic infection, as a result of random insertion of viral DNA 
into the host genome, by host processes during failed repair of the 
partially double-stranded DNA. This integrated DNA plays no role 
in viral replication, but plays an important and ill-defined role in 
the development of HCC. 
There are 5 phases of chronic infection which are not necessarily 
sequential and are of variable duration.[6,14]
1. The immune tolerant phase is characterised by HBeAg posi-
tivity, high levels of viral replication (high serum HBV DNA), normal 
transaminases, minimal or no hepatic necroinflammation and no or 
slow progression to fibrosis. During this phase, the rate of spontaneous 
HBeAg loss is low. This phase, which is more common and more 
prolonged in individuals infected perinatally or under the age of 5 
years, frequently persists into early adulthood and is frequent in SA.
2. The immune clearance phase (HBeAg-positive chronic 
hepatitis B) is characterised by HBeAg positivity, but lower levels of 
viral replication. The transaminases are elevated and histologically 
there is more severe necroinflammation and more rapid progression 
of fibrosis. This phase may last several weeks to years and, if 
successful, a sustained HBeAg seroconversion will occur with the 
development of anti-HBe. A successful HBeAg seroconversion is 
more likely to occur in individuals infected during adulthood.
3. The inactive HBV carrier or latency state (immune control 
phase) follows successful HBeAg to anti-HBe seroconversion and 
is characterised by very low (<2 000 IU/ml) or undetectable HBV 
DNA levels and normal transaminases. As a result of immunological 
control of the infection, these patients have a good prognosis, with 
a much lower risk of progression to cirrhosis or HCC. HBsAg loss 
and seroconversion to anti-HBs may occur spontaneously at a rate 
of 1 - 3% per year.
4. Five to 15% of individuals in the inactive HBV carrier state will 
develop HBeAg-negative chronic hepatitis B. This reactivation 
phase represents a later phase in the natural history of the disease 
and is more common in older men. Nucleotide substitutions in the 
precore and/or basal core promoter regions of the HBV genome 
result in HBV variants that are unable to express HBeAg, or 
which do so at very low levels. This phase is characterised by 
HBeAg negativity, fluctuating transaminases and HBV DNA levels, 
significant necroinflammation and progressive fibrosis. Low levels of 
hepatitis B immunoglobulin M core antibody (anti-HBc IgM) may 
be detected.
It is important, but often difficult, to distinguish this phase from 
the inactive HBV carrier state. Patients with HBeAg-negative chronic 
hepatitis B have a high risk of progression to cirrhosis, which may 
in turn lead to decompensation and the risk of HCC. At least 1 year 
follow-up, with 3 - 4-monthly monitoring of alanine transaminase 
(ALT) and HBV DNA levels, is required to confidently distinguish 
these two phases of the disease.[15-17]
Individuals in the inactive HBV carrier state may also revert back 
to HBeAg positivity and develop HBeAg-positive disease. 
5. Occult HBV infection is the term used to describe those cases 
where patients have cleared surface antigen but have detectable 
plasma HBV DNA. Serologically they are HBsAg negative, hepatitis 
B surface antibody (HBsAb) positive and anti-HBc IgG positive, 
yet they are positive for HBV DNA, albeit at very low levels 
(invariably <200 IU/ ml). While no liver disease is associated with 
occult infection, these individuals are at very high risk of reactivation 
of HBV with immune suppression, e.g. during use of rituximab 
(MabTheraR), and require prophylactic antiviral therapy.
3. Diagnosis 
In diagnosing chronic hepatitis B, HBV serological markers and HBV 
DNA levels must be carefully and correctly interpreted, to accurately 
decide on the phase of the chronic infection so that appropriate 
management, if required, can be instituted. 
3.1 HBV serological markers[5,18]
HBsAg:
• General and screening marker of infection
• First serological marker to appear
• Surrogate marker for transcriptionally active cccDNA
• Infection is considered chronic if HBsAg persists for >6 months.
HBeAg:
• Indicates active replication of virus 
• Absent or low in pre-core or basal core promoter mutations.
Anti-HBc total (HBcAb total):
• Includes both IgG and IgM HBcAb.
IgG anti-HBc:
• Most sensitive marker of past exposure to HBV as anti-HBs may 
be undetectable if HBV infection was acquired in childhood, as is 
common in SA.
IgM anti-HBc:
• Marker of acute infection or reactivation
• Strongly positive in acute infection and possible low positivity in 
reactivation or flare.[19]
Anti-HBs (HBsAb)
• Recovery and/or immunity to HBV
• Detectable after immunity is conferred by HBV vaccination.
Anti-HBe (HBeAb)
• Usually indicates HBeAg to anti-HBe seroconversion and that 
the virus is no longer replicating
• Also present in HBeAg-negative chronic hepatitis, with active 
replication due to mutants.
GUIDELINE
339  May 2013, Vol. 103, No. 5  SAMJ
3.2 Virological evaluation of HBV infection
• Serum HBV DNA quantification
• HBV genotype
• HBV resistance testing.
3.3 Role of HBV DNA testing[18]
• Can differentiate chronic HBeAg-negative disease from the 
inactive latency state (HBV DNA <2 000 IU/ml)
• Differentiates between occult hepatitis B (IgG anti-HBc 
positive, HBV DNA positive, but <200 IU/ml) and resolved 
infection (IgG anti-HBc positive, anti-HBs positive, HBV DNA 
negative)
• Changes in HBV DNA levels used to monitor response to 
therapy
• In patients adherent to therapy, increasing HBV DNA levels 
indicate the emergence of resistant variants 
• HBV DNA levels correlate with disease progression.[20-23] 
3.4  Immunological markers, DNA levels and ALT in 
HBV infection[16,24] 
See Table 2.
4.  Assessment of liver disease prior to 
therapy[5,6,16]
See Table 3.
4.1 Clinical history and physical examination
Include family history of HBV infection and HCC.
4.2 Assessment of the severity of the liver disease
• Liver profile including total bilirubin, conjugated bilirubin, ALT, 
aspartate transaminase (AST), alkaline phosphatase (ALP) and 
gamma-glutamyl transferase (GGT)
• Full blood count (FBC) including a differential count
• Serum albumin and international normalised ratio (INR) to 
assess synthetic function.
4.3 Viral serology
• HBsAg, anti-HBs, HBeAg and anti-HBe
• IgG anti-HBc (if assessing for occult HBV or previous cleared 
infection).
4.4 Viral replication
Serum HBV DNA quantified with real-time polymerase chain 
reaction (PCR).
4.5 Look for other co-factors 
• Viral co-infection: HCV, HIV
• Non-alchoholic fatty liver disease/alcoholic liver disease
• Iron overload
• Drug/toxin-induced injury.
Table 1. Key points: Natural history and pathogenesis
• Hepatitis B is a hepatotropic virus; liver injury occurs through immune-mediated killing of infected hepatocytes
• Chronicity occurs rarely when the HBV infection is contracted in adulthood, but is common in neonates and young children
• cccDNA is the transcriptional template for the viral mRNAs
• Newly synthesised cytoplasmic viral capsids containing mature viral DNA are transported to the nucleus, thereby replenishing cccDNA
• Cure is dependent on eradicating cccDNA
• Understanding the natural history and phases of chronic infection is essential when making management decisions
HBV = hepatitis B virus; cccDNA = covalently closed circular DNA; mRNA = messenger RNA.
Table 2. Immunological markers, DNA levels and ALT in HBV infection
Acute 
hepatitis B
Recovery from 
acute hepatitis B
Immune 
tolerant state
Chronic HBV disease Inactive HBsAg 
carrier state
Occult 
hepatitis BHBeAg positive HBeAg negative
HBsAg ü ü ü ü ü
Anti-HBs ü
Anti-HBc IgM ü
Anti-HBc IgG ü ü ü ü ü ü ü
HBeAg ü ü ü
Anti-HBe ü ü ü
HBV DNA (IU/ml) High Negative >20 000 IU/ml >20 000 IU/ml >2 000 IU/ml <2 000  IU/ml <200 IU/ml
ALT Elevated Normal Normal Elevated Elevated Normal Normal
HBsAg = hepatitis B surface antigen; Anti-HBs = detection of hepatitis B surface antibody; Anti-HBc = detection of hepatitis B core antibody; IgM = immunoglobulin M; IgG = immunoglobulin 
G; HBeAg = hepatitis B ‘e’ antigen; Anti-HBe = detection of hepatitis B ‘e’ antibody; HBV DNA = hepatitis B virus DNA; ALT = alanine transaminase.
Table 3. Key points in assessment of liver disease prior to therapy
•  Diagnosis and appropriate management of chronic hepatitis B require the correct interpretation of HBV serological markers and HBV DNA levels
• The main parameters generally available include ALT, HBsAg, HBeAg and HBV DNA levels
• The presence of necroinflammatory changes on biopsy suggests a higher likelihood of response to interferon-based therapy
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4.6 Liver biopsy
A liver biopsy is required to assess the 
degree of necroinflammation and fibrosis 
and is helpful in assessing the contribution 
of one or more comorbidities. It is generally 
indicated if the ALT is elevated and/or HBV 
DNA is >2 000 IU/ml, or when interferon-
based therapy is being considered. A biopsy 
is useful in the SA context to assess the 
need for treatment, as there has often 
been a prolonged immune tolerant phase 
and liver enzymes may be only marginally 
elevated. A liver biopsy is not required in 
patients with clinical evidence of cirrhosis 
or when nucleos(t)ide analogue (NUC) 
therapy is indicated, regardless of the grade 
of activity or stage of fibrosis. The risk of 
severe complications with liver biopsy is low 
(1/4 000 - 10 000). 
4.7  Ultrasound of the liver and 
Doppler studies of the portal vein
5.  Goals and endpoints 
of therapy[5,6,16] 
See Table 4. HBV infection cannot be 
eradicated completely with current available 
therapies because of the persistence of 
cccDNA, which acts as a viral reservoir in 
infected hepatocytes.[25] Even so, an ideal 
endpoint of treatment would be to achieve 
viral eradication with sustained HBsAg loss, 
with/without seroconversion to anti-HBs 
antibodies, as HBsAg is a surrogate marker 
for transcriptionally active cccDNA. [26,27] 
However, this is as yet uncommon and 
hence a broad goal of therapy is to prevent 
or reverse disease progression to cirrhosis, 
end-stage liver disease or HCC. This can be 
achieved by suppressing HBV replication, 
with a consequent improvement in necro -
inflammation and fibrosis that lowers the 
risk of cirrhosis and HCC.[20-22,28] 
Once cirrhosis is established, preventing 
decompensation, HCC or death is the 
primary treatment goal. In those patients 
with early decompensation, suppression 
of HBV replication can improve synthetic 
function and decrease the Child-Pugh/
model for end-stage liver disease (MELD) 
score, and may delay the need for liver 
transplantation. In those with end-stage 
liver disease, suppression of HBV replication 
prior to transplantation reduces the risk of 
recurrence. 
5.1  Endpoints of treatment: HBeAg-
positive disease
• The ideal endpoint is sustained HBsAg 
loss due to therapy, with/without the 
development of anti-HBs
Chronic hepatitis B treatment algorithm
HBeAg positive
HBV DNA
HBV DNA ≥20 000 IU/ml
Normal >ULN
ALT
· Monitor ALT 3 - 6-monthly 
  (? immune tolerance)
· If ALT elevated, consider 
  liver biopsy and 
  treatment (≥A2 or ≥F2)
· Consider liver 
  biopsy and 
  treatment  
  (≥A2 or ≥F2)
ALT ULN: 19 IU/ml (female) and 30 IU/ml (male)
HBV DNA <20 000 IU/ml
ALT
Normal >ULN
· Monitor ALT and HBV  
  DNA every 6 - 12 months
· If ALT elevated, consider  
  liver  biopsy and 
  treatment (≥A2 or ≥F2)
· Consider liver 
  biopsy and 
  treatment  
  (≥A2 or ≥F2)
Chronic hepatitis B treatment algorithm
HBeAg negative
HBV DNA
HBV DNA ≥2 000 IU/ml
Normal >ULN
ALT
· Monitor ALT 3 - 6-monthly 
· If ALT elevated, consider 
  liver  biopsy and 
  treatment (≥A2 or ≥F2)
· Consider liver 
  biopsy and 
  treatment  
  (≥A2 or ≥F2)
ALT ULN: 19 IU/ml (female) and 30 IU/ml (male)
HBV DNA <2 000 IU/ml
ALT
Normal >ULN
· Monitor ALT and HBV DNA 
  every 6 - 12-months to 
  conrm inactive carrier 
  state
· If ALT elevated, consider  
  liver  biopsy and 
  treatment (≥A2 or ≥F2)
· Consider liver 
  biopsy and 
  treatment  
  (≥A2 or ≥F2)
Fig. 1. Treatment algorithm for HBeAg-positive disease. HBeAg = hepatitis B ‘e’ antigen; HBV DNA = 
hepatitis B DNA; ULN = upper limit of normal; ALT = alanine transaminase. 
Chronic hepatitis B treatment algorithm
HBeAg positive
HBV DNA
HBV DNA ≥20 000 IU/ml
Normal >ULN
ALT
· Monitor ALT 3 - 6-monthly 
  (? immune tolerance)
· If ALT elevated, consider 
  liver biopsy and 
  treatment (≥A2 or ≥F2)
· Consider liver 
  biopsy and 
  treatment  
  (≥A2 or ≥F2)
ALT ULN: 19 IU/ml (female) and 30 IU/ml (male)
HBV DNA <20 000 IU/ml
ALT
Normal >ULN
· Monitor ALT and HBV  
  DNA every 6 - 12 months
· If ALT elevated, consider  
  liver  biopsy and 
  treatment (≥A2 or ≥F2)
· Consider liver 
  biopsy and 
  treatment  
  (≥A2 or ≥F2)
Chronic hepatitis B treatment algorithm
HBeAg negative
HBV DNA
HBV DNA ≥2 000 IU/ml
Normal >ULN
ALT
· Monitor ALT 3 - 6-monthly 
· If ALT elevated, consider 
  liver  biopsy and 
  treatment (≥A2 or ≥F2)
· Consider liver 
  biopsy and 
  treatment  
  (≥A2 or ≥F2)
ALT ULN: 19 IU/ml (female) and 30 IU/ml (male)
HBV DNA <2 000 IU/ml
ALT
Normal >ULN
· Monitor ALT and HBV DNA 
  every 6 - 12-months to 
  conrm inactive carrier 
  state
· If ALT elevated, consider  
  liver  biopsy and 
  treatment (≥A2 or ≥F2)
· Consider liver 
  biopsy and 
  treatment  
  (≥A2 or ≥F2)
Fig. 2. Treatment algorithm for HBeAg-negative disease.
Table 4. Key points in goals of therapy
• Chronic hepatitis B infection cannot be eradicated with currently available therapies
• In chronic hepatitis B, the goal of therapy is to prevent the progression to cirrhosis
• In HBV cirrhosis, the goal of therapy is to prevent decompensation and HCC
•  In decompensated liver disease, the goal of therapy is to improve synthetic function through 
viral suppression
•  The ideal endpoint of therapy for both chronic HBeAg-positive and chronic HBeAg-negative 
disease is HBsAg loss with or without seroconversion to anti-HBs, as this correlates with the 
loss of transcriptionally active cccDNA
HCC = hepatocellular carcinoma; HBeAg = hepatitis B ‘e’ antigen; HBsAg = hepatitis B surface antigen; cccDNA = 
covalently closed circular DNA.
GUIDELINE
341  May 2013, Vol. 103, No. 5  SAMJ
• Durable HBeAg loss and seroconversion to anti-HBe 
• Durable suppression of HBV DNA to low or undetectable levels
• Normalisation of ALT.
5.2 Endpoints of treatment: HBeAg-negative disease
• The ideal endpoint is sustained HBsAg loss off therapy, with/
without the development of anti-HBs
• Durable suppression of HBV DNA to low or undetectable levels
• Normalisation of ALT.
6. Definitions of response[6] 
Responses may be biochemical, serological, virological or histological 
and vary according to the type of therapy.
6.1 Interferon-based therapy
• Primary non-response is not well established
• A virological response is an HBV DNA concentration <2 000 
IU/ml, evaluated at 6 months, end of therapy; and at 6 and 12 
months after completion of therapy
• A sustained off-treatment virological response is defined 
as HBV DNA levels <2 000 IU/ml for at least 12 months after 
completion of treatment
• A serological response in patients with HBeAg-positive chronic 
hepatitis B is HBeAg seroconversion to anti-HBe positive.
6.2 NUC therapy
• Primary non-response is a <1 log10 IU/ml decrease in HBV 
DNA level from baseline at 3 months of therapy.
• A virological response is undetectable HBV DNA by real-time 
PCR assay within 48 weeks of therapy; evaluated every 3 - 6 
months during therapy depending on the severity of the liver 
disease and type of NUC.
• Partial virological response is a >1 log10 IU/ml decrease in 
HBV DNA, but detectable HBV DNA by real-time PCR assay.
• A partial virological response should be assessed at 24 weeks 
for patients on lamivudine which is moderately potent but has 
a low genetic barrier to resistance and at 48 weeks in patients 
on entecavir or tenofovir which are highly potent with a higher 
genetic barrier to resistance.
• Virological breakthrough is a confirmed increase in HBV DNA 
level >1 log10 IU/ml compared with the nadir HBV DNA level 
on therapy. This usually precedes a biochemical breakthrough. 
The main causes of virological breakthrough are poor adherence 
to therapy or the development of resistance. Resistance may 
result in primary treatment failure or virological breakthrough 
on therapy.
• A sustained off-treatment virological response is defined 
as HBV DNA levels <2 000 IU/ml for at least 12 months after 
completion of treatment.
Histological response is a ≥2 points (histological activity index 
(HAI)) decrease in necroinflammatory activity without further 
progression in fibrosis compared to the pre-treatment histology. 
Complete response is a sustained off-treatment virological 
response together with loss of HBsAg.
7. Available therapies
Six drugs are currently available in SA for treating chronic hepatitis B:
• Standard interferon alpha-2a and -2b
• Pegylated interferon alpha-2a 
• Lamivudine
• Entecavir
• Tenofovir, which is available for off-label use alone or in 
combination with emtricitabine (it is not yet registered for the 
treatment of hepatitis B in SA, but is registered by both the 
European regulatory authority and the FDA for hepatitis B).
The recommended first-line monotherapies include interferon-
based therapy and the NUCs tenofovir and entecavir. It is important 
to realise that all patients with chronic hepatitis B may be potential 
candidates for treatment, but it is important to choose the appropriate 
treatment at the appropriate time.
8. Indications for treatment
The 2008 NIH guideline[8] regarding indications for hepatitis B 
treatment suggests the following:
8.1 Patients who must be treated[6,20,29-33]
• Acute liver failure – in order to suppress ongoing HBV 
replication in an attempt to prevent ongoing hepatocyte necrosis 
• Decompensated cirrhosis
• Advanced fibrosis or cirrhosis and detectable serum HBV DNA, 
even if normal ALT
• Patients receiving chemotherapy, rituximab or immuno-
suppressive therapy. 
8.2 Patients who should be considered for therapy[5,6,7] 
• HBeAg-positive chronic hepatitis B
• HBeAg-negative chronic hepatitis B.
The decision to treat these patients and the type of treatment is 
clinically based on the combination of:
• Serum aminotransferase levels
• Serum HBV DNA levels
• HBV genotype and HBV mutations
• Histological grade and stage of the disease 
• Race and age of the patient
• Family history of hepatitis B-related cirrhosis and HCC 
• Co-factors such as alcohol, iron overload, and co-infection with 
either the hepatitis C virus (HCV) or HIV.
8.3 Patients who do not require immediate therapy[6]
• Patients in the immune tolerant phase (<30 years with 
persistently normal ALT, no evidence of liver disease, and no 
family history of cirrhosis or HCC)
• Patients in the inactive carrier or latency phase (if HBV DNA 
>2 000 and <20 000 IU/ml and no evidence of liver disease, 
monitor ALT every 3 months and HBV DNA every 6 - 12 
months for 3 years, then lifelong as for inactive carriers)
• Occult hepatitis B.
9. Treatment of chronic hepatitis B
Over the past 4 years, the 4 major liver societies – the AASLD, EASL, 
APASL and WGO – have published their updated guidelines on the 
management of HBV infection.[5-7,9] 
9.1 Treatment criteria for chronic hepatitis B 
The AASLD, EASL and APASL all recommend slightly different HBV 
DNA and ALT levels for initiation of treatment (Table 5). However, 
it is important to treat liver disease and not only base the need for 
therapy on ALT and HBV DNA levels. In SA, patients frequently have 
a long immune tolerant phase and ALT is frequently <2 x the upper 
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 limit of normal (ULN) with high HBV DNA levels. Therefore, liver 
biopsy plays an important role in determining the need for therapy and 
the type of therapy. If the liver biopsy shows moderate to severe necro-
inflammation and/or fibrosis using a standardised scoring system 
(≥A2 or ≥F2 on Metavir scoring), patients should be considered for 
treatment. Other important factors determining the need for therapy 
and type of therapy include patient’s age and race, potential future 
pregnancies in females, family history of HCC, co-factors (alcohol, 
iron overload and viral co-infection) and anticipated compliance with 
potentially lifelong NUC therapy. Antiviral therapy may also need to 
be considered in healthcare workers without active liver disease if they 
are engaged in exposure-prone procedures, in order to suppress viral 
replication. It is important to continue monitoring all patients with 
chronic HBV infection who are not on therapy as they may require 
treatment in the future. 
See SA treatment algorithms for chronic hepatitis B (HBeAg-
positive and HBeAg-negative disease) (Figs 1 and 2).
10. Management strategies 
Once a decision has been made to treat a patient with chronic 
hepatitis B, all the pros and cons of interferon-based therapy v. NUCs 
need to be considered and discussed with the patient (Table 6).
10.1 General measures
All patients should be screened for IgG anti-HAV, anti-HCV and anti-
HIV before treatment is initiated. Those found not to be immune to 
hepatitis A should be vaccinated. 
10.2 Adverse effects of interferon-based therapy
• Initial influenza-like illness 
• Fatigue
• Anorexia and weight loss
• Alopecia
• Myelosuppression with neutropenia and thrombocytopenia
• Hypo- and hyper-thyroidism.
Table 6. Interferon-based v. NUC treatment
Treatment Pegylated interferon NUCs
Route Subcutaneous injection Oral
Duration of treatment Finite duration: 12 months Long duration, years to lifelong
Antiviral activity Moderate antiviral effects 
Mostly immunomodulatory effects
Potent antiviral activity
HBsAg loss 3 - 7% after 1 year of treatment, depending 
on whether HBeAg positive or negative
0 - 3% after 1 year of treatment, depending on agent 
and whether HBeAg positive or negative
HBe seroconversion 25 - 35%, 3 - 5 years after completion of treatment ~20% at 1 year: sustainability poor off treatment
Viral resistance None 0 - 25% after 1 year, depending on agent
Adverse effects Frequent Uncommon
NUCs = nucleos(t)ide analogues; HBsAg = hepatitis B surface antigen; HBe = hepatitis B ‘e’.
Table 5. Major liver society guidelines for treatment of chronic hepatitis B
Major liver society guidelines*
HBeAg positive HBeAg negative
HBV DNA
IU/ml ALT
HBV DNA
IU/ml ALT
EASL 2012[6] >2 000 >ULN† >2 000 >ULN†
APASL 2012[7] ≥20 000 2 - 5 x ULN† ≥2 000 >2 x ULN†
AASLD 2009[5] >20 000 >2 x ULN‡
Observe for 3 - 6 months
Initiate Rx, if no spontaneous 
HBeAg clearance
Or (+) biopsy
≥20 000** ≥2 x ULN‡ 
  or
(+) biopsy
HBeAg = hepatitis B ‘e’ antigen; ULN = upper limit of normal; HBV DNA = hepatitis B virus DNA; EASL = European Association for the Study of the Liver; APASL; Asia-Pacific Association 
for the Study of the Liver (APASL); AASLD = American Association for the Study of Liver Disease.
* The levels of elevation of ALT and HBV DNA that warrant consideration of treatment and the need for liver biopsy are not agreed upon by the 3 major liver societies.
† Upper limit of laboratory normal.
‡ 30 U/l for men and 19 U/l for women.
** In patients older than 40 years of age, 2 000 IU/ml should be considered as a cut-off for treatment.
AASLD: 
HBeAg-positive disease: Recommends liver biopsy if ALT is 1 - 2 x ULN and: (1) HBV DNA > 20 000 IU/ml; (2) >40 years; or (3) family history of HCC. 
Consider therapy if histological disease.
HBeAg-negative disease: Liver biopsy if ALT 1 - 2 x ULN and HBV DNA 2 000 - 20 000 IU/ml: Consider therapy if histological disease.
EASL: 
Recommends liver biopsy and treatment if there is moderate to severe necroinflammation and/or fibrosis (≥grade A2 ≥stage F2 by Metavir scoring). If patients meet the treatment criteria 
for HBV DNA and histological severity of liver disease, treatment can be initiated even if ALT is normal.
APASL:
HBeAg positive disease: Recommends liver biopsy if HBV DNA  ≥20 000 IU/ml and: (1) ALT 1 - 2 x ULN and >40 years.
Treat if moderate to severe inflammation and/or fibrosis.
HBeAg-negative disease: Liver biopsy if HBV DNA ≥2 000 IU/ml and ALT 1 - 2 x ULN and >40 years.
Treat if moderate to severe inflammation and/or fibrosis.
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• Emotional lability and depression 
• Retinal changes and impaired vision
• Flare in ALT occurs in 30 - 40% of patients on treatment.
The main advantages of interferon alpha-based treatment are 
the lack of resistance, the finite duration of therapy, the possibility 
of immune-mediated clearance of HBV and the slightly higher 
probabilities of HBeAg to anti-HBe and HBsAg to anti-HBs 
seroconversions rates after the 1st year of treatment. There is also a 
cumulative benefit, as ongoing HBeAg loss continues after cessation 
of therapy (25 - 35%, 3 - 5 years after therapy)[34] as does HBsAg 
loss.
10.3 Interferon alpha and pegylated interferon alpha 
therapy contraindications[5,16]
• Decompensated cirrhosis
• Fulminant hepatitis B
• Pregnancy
• Significant cardiopulmonary disease
• Uncontrolled seizures 
• Active autoimmune disease
• Psychiatric disease 
• Chemotherapy. 
10.4 Factors favouring interferon alpha or pegylated 
interferon alpha as initial therapy[5,6]
10.4.1 Favourable predictors of response
10.4.1.1 Pretreatment 
HBeAg-positive chronic hepatitis B (predictors of anti-HBe sero-
conversion)
• Low viral load: HBV DNA <1 x 107 IU/ml. Note that definitions 
of low viral load vary from <2 x 106 to <2 x 108 IU/ml
• ALT >2 - 5 x ULN
• Active necroinflammation on biopsy (Metavir Grade ≥A2)
• Genotype A and B > C and D,[35-37] although choice of treatment 
should not be based on genotype alone.
HBeAg-negative chronic hepatitis B
• No strong pre-treatment predictors of virological response.
10.4.1.2 During treatment
HBeAg-positive chronic hepatitis B
• HBV DNA <20 000 IU/ml at 12 weeks of pegylated interferon 
alpha therapy is associated with a 50% chance of anti-HBe 
seroconversion.
• ALT flare followed by an HBV DNA decrease is associated with 
more frequent anti-HBe seroconversion.
• HBeAg decrease to <100 IU/ml at week 24 may predict anti-HBe 
seroconversion, if HBeAg quantification is available.[38]
• HBsAg level <1 500 IU/ml at week 12 of pegylated interferon alpha 
therapy is associated with a 57% chance of sustained immune 
control (anti-HBe seroconversion 6 months post therapy).[39] 
HBsAg >20 000 IU/ml at week 12 is associated with low rate of 
anti-HBe seroconversion and treatment can be stopped.
HBeAg-negative chronic hepatitis B
• HBV DNA <20 000 IU/ml at 12 weeks of pegylated interferon 
alpha therapy is associated with a 50% chance of a sustained 
off-treatment response (normal ALT and HBV DNA <2 000 
IU/ml)[38,40] 
• Decreases in quantified HBsAg levels of >0.5 log10 IU/ml and 
>1 log10 IU/ml at weeks 12 and 24 of therapy, respectively, have 
high predictive values for undetectable HBV DNA 24 weeks post 
completion of treatment.[41]
10.4.2 Patient demographics[5,34]
Younger patients, and particularly young women wanting future 
pregnancies.
10.4.3 No co-infection with HIV
10.4.4 HCV co -infection with HBV
10.5 Factors favouring NUC as initial therapy
• High HBV DNA levels (>2 x 108 IU/ml)
• Patient demographics: older patients
• Ability to commit to potentially lifelong therapy
• HIV co-infection
• Contraindications to interferon-based therapy 
• HBV genotype does not influence response to NUCs.
For both interferon-based and NUC therapy: low HBV DNA levels 
<1 x 107 IU/ml, ALT >2 - 5 x ULN and active necroinflammation on 
biopsy are predictive of anti-HBe seroconversion. 
10.6 Duration of treatment and dosage regimens[5,6]
10.6.1 Pegylated interferon alpha-2a
A 48-week course of 180 μg pegylated interferon alpha-2a, given 
subcutaneously weekly, should be considered as first-line therapy in 
both HBeAg-positive and HBeAg-negative disease in patients with 
a favourable pre-treatment profile (ALT >3 x ULN, HBV DNA 
<2 x 106 IU/ml, genotype A and B and active necroinflammation 
on liver biopsy). 
If the HBV DNA levels are detectable, but <2 000 IU/ml at 48 
weeks, there is no need for ongoing NUC treatment unless the 
patient is cirrhotic or has ≥F3 fibrosis. However, ongoing monitoring 
is required. If the HBV DNA levels are >2 000 IU/ml at 48 weeks, 
ongoing treatment with NUCs is required. 
10.6.2 Interferon alpha-2a or -2b 
Interferon alpha-2a or -2b given subcutaneously 3 times a week for 
16 - 24 weeks is less expensive than pegylated interferon alpha and 
is effective in carefully selected patients.
Potential suitable candidates are HBeAg positive with high baseline 
ALT levels, low HBV DNA levels and active necroinflammation on 
biopsy. 
The dosage of interferon alpha can be titrated from 1 to 10 MU 
subcutaneously 3 times a week or 5 MU daily. In the SA setting, dosages 
seldom exceed 5 million units 3 times a week and are usually 3 million 
units 3 times a week. The recommended dosage for children is 6 MU/ m2 
3 times a week with a maximum dosage of 10 MU 3 times a week.
A liver biopsy is mandatory when considering treatment with 
either pegylated interferon alpha-2a or standard interferon alpha.
10.6.3 NUCs
A finite duration of treatment may be achievable in HBeAg-positive 
patients who achieve anti-HBe seroconversion and undetectable 
HBV DNA levels on treatment.
This is only possible with potent NUCs such as entecavir and 
tenofovir which have a high genetic barrier to resistance. Once 
HBeAg to anti-HBe seroconversion has occurred, treatment should 
be consolidated and continued for at least 1 year. Careful follow-
up after the cessation of successful treatment is important as up 
to 20% of patients may relapse and become HBeAg positive again. 
Continuation of therapy until HBsAg seroconversion is advisable.[42] 
Patients with HBeAg-negative chronic hepatitis B and those with 
cirrhosis require lifelong treatment with NUCs.
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Lamivudine: The recommended dosage for adults with normal 
renal function (creatinine clearance >50 ml/min) is 100 mg/day. 
Dosage reduction is necessary in patients with impaired renal 
function. A practical issue is that given the availability and use 
of lamivudine in the treatment of HIV in SA, the use of the 150 
mg tablet daily in the treatment of hepatitis B mono-infection is 
acceptable. 
The recommended dosage for children is 3 mg/kg/day with a 
maximum dosage of 100 mg/day. A liquid formulation for children 
is available. Patients who are HIV/HBV co-infected should receive 
lamivudine 150 mg bd. 
Tenofovir: The recommended dosage for adults with normal 
renal function (creatinine clearance >50 ml/min) is 300 mg per day. 
It is necessary to reduce the dosage in patients with impaired renal 
function. 
Entecavir: The recommended dosage for adults with normal 
renal function (creatinine clearance >50 ml/min) is 0.5 mg daily if 
lamivudine naïve and 1 mg daily if previously exposed to lamivudine 
or if lamivudine refractory or resistant. Dosage reduction is necessary 
in patients with impaired renal function. 
11.  Treatment of patients with 
compensated cirrhosis 
Treatment should be considered in patients with compensated 
cirrhosis and detectable HBV DNA levels.[6,20,43]
Interferon-based therapy can be used in compensated cirrhosis, 
but does increase the risk of infections and decompensation. If 
interferon-based therapy is used, it is important to titrate the dose of 
standard interferon/pegylated interferon with careful monitoring of 
the FBC, differential count and ALT. The duration of therapy (16 - 24 
weeks for standard interferon and 48 weeks for pegylated interferon) 
should be timed from the point that the maximum dosage was 
achieved during the titration.
NUCs are well tolerated and a potent NUC with a high genetic 
barrier to resistance should be used, e.g. tenofovir or entecavir. If 
lamivudine is used, it is advisable that it be combined with tenofovir. 
Long-term therapy is required and regular monitoring of HBV DNA 
levels is essential. Any decompensation on NUC therapy could be due 
to the natural progression of the disease or the development of HCC, 
but it is critical to first exclude non-compliance or the development 
of resistance as a factor. Current evidence suggests that prolonged and 
effective suppression of HBV DNA replication can stabilise and even 
prevent or delay the need for liver transplantation.[20] NUC therapy is 
usually lifelong. 
12.  Treatment of decompensated 
cirrhosis
All patients with decompensated cirrhosis should be considered 
for urgent treatment. Interferon-based therapy is contraindicated 
and only NUCs should be used.[5,6,8,16] Treatment is indicated even 
if the HBV DNA level is low or undetectable, in order to prevent 
flares/reactivation. Treatment with NUCs may lead to clinical 
improvement over a period of 3 - 6 months. If there is ongoing 
deterioration, treatment with NUCs is important to suppress the 
HBV DNA and thereby decrease the risk of hepatitis B recurrence 
post-liver transplantation. In unstable patients with deteriorating 
renal function, it is advisable to start with lamivudine and add in 
tenofovir once the clinical condition has stabilised. If entecavir is 
used, the recommended dosage is 1 mg daily and patients should be 
monitored for lactic acidosis. Lifelong treatment is recommended.
13.  Treatment of patients in the 
inactive carrier state or the immune 
tolerant phase who require 
immunosuppressive therapy, 
rituximab or chemotherapy
• HBsAg and IgG anti-HBc should be tested before the 
introduction of immunosuppressive therapy, rituximab or 
chemotherapy.[44-46] 
• If either HBsAg or IgG anti-HBc is positive, HBV DNA levels 
should be measured.
• If HBsAg negative, IgG anti-HBc positive and HBV DNA is 
detectable, NUC therapy is indicated as for HBsAg-positive 
patients.
• If HBsAg negative, IgG anti-HBc positive and HBV DNA is 
undetectable, no treatment is needed, but ALT and HBV DNA 
levels should be monitored at regular intervals (1 - 3-monthly) 
depending on immunotherapy type; treatment should be initiated 
when HBV DNA becomes detectable. If regular HBV DNA level 
monitoring is not possible, NUC therapy is also indicated.
• If HBsAg positive and HBV DNA <2 000 IU/ml, then treatment 
with an NUC should be continued for 12 months after 
completion of immunosuppressive therapy. Lamivudine can be 
used, if anticipated duration of treatment is not >12 months and 
HBV DNA level is <2 000 IU/ml.
• If HBsAg positive and HBV DNA ≥2 000 IU/ml, an NUC with 
a high genetic barrier to resistance (tenofovir or entecavir) 
should be used and continued until the usual treatment 
endpoint has been achieved. Tenofovir or entecavir should also 
be used, if lengthy and repeated cycles of immunosuppression 
are needed.
• Where possible, antiviral therapy should be initiated before 
the onset of immunosuppressive therapy, rituximab or 
chemotherapy, and HBV DNA levels should be undetectable.[47]
• IgG anti-HBc-positive patients receiving bone marrow or stem 
cell transplants should also receive NUC prophylaxis.
14. Combination therapy
There are as yet no data confirming the advantage of combination 
therapy.
The most commonly used combination therapies are tenofovir plus 
lamivudine or tenofovir plus emtricitabine, which may be considered 
in the following situations:[6,48,49]
• Patients with high baseline HBV DNA levels who are at greater 
risk of developing resistance
• Cirrhotic patients in whom a biochemical breakthrough associated 
with the development of resistance is potentially life threatening
• Post-liver transplantation together with hepatitis B immune 
globulin (HBIG)
• HIV/HBV co-infection where there is a risk of resistance with 
monotherapy
• A suboptimal response to an initial drug, especially in the 
presence of high HBV DNA levels
• Established resistance to an NUC.
15. Monitoring therapy[5,6]
15.1 Pegylated interferon alpha (Table 7)
15.1.1. During treatment
• FBC, differential count, INR and liver profile should be 
performed at least monthly. The baseline results and effects of 
therapy may dictate more frequent testing.
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• Serum HBV DNA levels should be measured at weeks 12 and 24 on 
treatment to assess the primary response and at end of treatment.
• Serum thyroid-stimulating hormone (TSH) every 12 weeks.
• Monitor for known side-effects of interferon.
15.1.2 Post treatment
• FBC, differential count, liver profile, TSH, HBV DNA levels, 
HBeAg/anti-HBe (if initially HBeAg positive) should be 
measured every 12 weeks during the first 24 weeks post 
treatment and then 6 - 12-monthly
• FBC, differential count, liver profile and DNA levels may 
need more frequent monitoring if patient is unstable
• 6 - 12-monthly HBsAg monitoring.
HBeAg-positive disease: Aim for a sustained off-treatment anti-
HBe seroconversion, ALT normalisation and HBV DNA <2 000 
IU/ml. 
Undetectable HBV DNA by real-time PCR is associated with 
increased chance of HBsAg loss:
• Test for HBeAg and anti-HBe at weeks 24 and 48 of treatment 
and 24 weeks post treatment. HBsAg should be checked 6 
monthly after HBeAg to anti-HBe seroconversion if HBV DNA 
is undetectable.
• If a 1 log10 reduction in HBV DNA levels is not achieved at 12 
weeks, the pegylated interferon alpha should be stopped and an 
NUC introduced.
HBeAg-negative disease: Aim for a sustained off-treatment 
virological response with HBV DNA levels <2 000 IU/ml and ALT 
normalisation.
Undetectable HBV DNA by real-time PCR is associated with 
increased chance of long-term HBsAg loss:
• Monitor HBsAg 6-monthly, if HBV DNA levels undetectable
• If a 1 log10 reduction in HBV DNA levels is not achieved at 12 
weeks, the pegylated interferon alpha should be stopped and an 
NUC introduced.
15.2 NUC therapy (Table 8)
• FBC, differential count, INR, liver profile, amylase and 
creatinine assessment should be performed at weeks and 4 and 
then 3-monthly if stable.
• HBV DNA levels are measured at week 12 to assess virological 
response and then every 12 - 24 weeks.
• HBV DNA monitoring is critical to detect treatment failure. 
Undetectable HBV DNA levels by real-time PCR (level of 
detection <10 - 15 IU/ml) need to be achieved to prevent the 
development of resistance.
• Partial responses (HBV DNA level detectable but <2 000 IU/ ml) 
are assessed at 24 weeks for lamivudine and at 48 weeks for 
tenofovir and entecavir. If HBV DNA levels are still positive, but 
declining at 48 weeks on tenofovir or entecavir, monotherapy 
can be continued.[49] 
• NUCs require dosage adjustments in the setting of renal 
impairment. 
15.2.1 HBeAg-positive disease
• HBeAg and anti-HBe should be measured every 6 - 12 months. 
Consider stopping NUCs 48 weeks after HBeAg seroconversion; 
however, this must be carefully considered and if it is stopped, 
the patient must be monitored closely. In patients with cirrhosis 
or previous hepatic decompensation, NUCs should never be 
stopped.
• HBsAg should be checked 6-monthly after anti-HBe sero-
conversion.
15.2.2 HBeAg-negative disease
• A virological response (HBV DNA < 2000 IU/ml) is associated 
with disease remission
• Monitor HBsAg 6-monthly, if HBV DNA levels are undetectable.
(See Table 8 for key points for monitoring NUC therapy.)
16.  Management of nucleos(t)ide 
resistance[5,6]
• Lamivudine resistance: Add tenofovir or switch to tenofovir/
emtricitabine. Screen for tyrosine-methionine-aspartate-aspartate 
(YMDD) mutations, if available.
• Entecavir resistance: Add or switch to tenofovir or switch to 
tenofovir plus emtricitabine. The safety of an entecavir/tenofovir 
combination is not known.
• Tenofovir: resistance has not yet been described.
Table 7. Key points in monitoring interferon-based therapy
Time point Key points 
During treatment
Every 4 weeks • FBC, differential, INR 
• Liver profile
Every 12 weeks • TSH 
• HBV DNA levels
Every 24 weeks •  HBeAg/anti-HBe (if initially HBeAg positive) 
Post-treatment
 Every 12 weeks 
during the first 
24 weeks, then 
6 - 12-monthly
• FBC, Differential 
• Liver profile
• TSH
• HBV DNA levels
•  HBeAg/anti-HBe (if initially HBeAg 
positive) 
•  HBsAg 6-monthly after HBe 
seroconversion, if HBV DNA undetectable
Table 8. Key points in monitoring NUC therapy
Time point Key points
Weeks 1 and 4 •  Liver profile, serum creatinine and 
amylase
• FBC, differential, INR
Every 12 weeks • Liver profile
•  Serum creatinine (if receiving tenofovir or 
entecavir)
Every 12 - 24 weeks • HBV DNA levels
Every 24 weeks •  HBeAg/anti-HBe (if initially HBeAg positive) 
Every 6 - 12 months •  HBsAg in HBeAg-positive patients after 
anti-HBe seroconversion
•  HBsAg in HBeAg-negative patients with 
persistently undetectable HBV DNA
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17.  Monitoring of patients not 
considered for therapy[5]
17.1  Immune tolerant phase (HBeAg positive, HBV 
DNA >20 000 IU/ml, normal ALT)
• ALT and HBV DNA levels every 3 - 6 months, more often if ALT 
becomes elevated.
• HBeAg status every 6 - 12 months.
• If ALT levels are 1 - 2 x ULN, recheck ALT every 1 - 3 months. 
Consider liver biopsy if the patient is >40 years of age, and if 
ALT is borderline or mildly elevated on serial tests. Consider 
treatment if biopsy shows moderate/severe inflammation or 
significant fibrosis.
• If ALT is >2 x ULN for 3 - 6 months, HBeAg positive and HBV 
DNA is >20 000 IU/ml, consider liver biopsy and treatment.
• Consider screening for HCC in the relevant population.
17.2  Inactive HBsAg carrier state (HBsAg positive, HBV 
DNA <2 000 IU/ml, normal ALT)
• Monitor ALT and HBV DNA levels every 3 - 4 months for 1 year.
• If ALT is persistently normal and HBV DNA <2 000 IU/ml, then 
check ALT and HBV DNA every 6 - 12 months.
• If ALT >1 - 2 x ULN, check serum HBV DNA level and exclude 
other causes of liver disease. Consider liver biopsy if ALT is 
borderline or mildly elevated on serial tests, or if HBV DNA is 
persistently ≥2 000 IU/ml. Consider treatment if biopsy shows 
moderate/severe inflammation or significant fibrosis.
• Consider screening for HCC in relevant populations.
18. Special patient populations[5,6]
18.1 Pregnancy
Interferon-based therapy is contraindicated in pregnancy and family 
planning should always be discussed before embarking on therapy. 
Lamivudine and entecavir are category C drugs and tenofovir is a 
category B drug. Data in HIV-positive pregnant women suggest that 
the use of lamivudine, emtricitabine and tenofovir is safe.[50,51] There is 
evidence that in HBsAg-positive women with high levels of viraemia 
(HBV DNA >2 x 107 IU/ml), treatment with lamivudine during the last 
trimester reduces the risk of intra-uterine and perinatal transmission 
of HBV, when given in addition to HBIG and HBV vaccination at 
delivery.[52] It is now recommended that lamivudine or tenofovir should 
be used in the last trimester in HBsAg-positive women with high viral 
loads (serum HBV DNA >1 x 106-7 IU/ml), to prevent intra-uterine 
and perinatal HBV transmission. NUC therapy can be discontinued 
3 months post-delivery if only required for prevention of perinatal 
transmission.
HBV-infected women should be monitored closely after delivery 
as flares may occur.[53] 
18.2 Healthcare workers
Healthcare workers who are HBsAg positive and have HBV DNA 
levels ≥2 000 IU/ml should be treated with a potent antiviral agent 
with a high genetic barrier to resistance, such as tenofovir or 
entecavir. The HBV DNA level should preferably be undetectable 
or at least <2 000 IU/ml before such an individual may return to 
exposure-prone procedures.[6]
18.3 Children
Chronic hepatitis B is typically benign in children as they are usually 
in the immune tolerant phase. Only standard interferon alpha, 
lamivudine and adefovir have been evaluated in children.[54,55]
In children with abnormal liver profiles, one should be guided 
by the histology in determining the need for treatment. In SA the 
choice is between standard interferon alpha or lamivudine therapy. 
Long-term use of lamivudine is associated with the development of 
resistance (70% at 5 years).
18.4 Dialysis and renal transplant patients
The dosages of lamivudine, tenofovir and entecavir need to be 
carefully adjusted in patients with impaired renal function. Tenofovir 
or entecavir can be used in renal transplant patients and the dosage 
adjusted according to the renal graft function. Interferon-based 
therapy is not recommended in renal transplant recipients because 
of the risk of graft rejection. All HBsAg-positive patients undergoing 
renal transplantation should receive prophylactic NUC therapy.
18.5 Extrahepatic disease
Patients with chronic hepatitis B and active HBV replication who 
present with extrahepatic disease (polyarteritis nodosa, glomerulo-
nephritis) should be considered for therapy with NUCs, but efficacy 
is variable. Lamivudine has been most widely used, but tenofovir or 
entecavir are now preferable, provided renal function permits their 
use. Plasmapheresis and steroids, in combination with an NUC, have 
been used in the initial phase of treatment. Interferon-based therapy 
may worsen immune-mediated extra-hepatic manifestations.
18.6 HBV/HCV co-infected patients
HCV co-infection accelerates the progression of liver disease and 
increases the risk of HCC. However, in co-infected patients, HBV 
DNA levels tend to be low and the hepatitis C virus is usually 
responsible for disease activity. Liver biopsy and HBV DNA levels 
are useful in establishing the contribution of hepatitis B to disease 
activity. The patient should be treated with pegylated interferon 
alpha and ribavirin, as indicated for chronic hepatitis C.[56] Sustained 
virological responses are similar to reponses in those who are mono-
infected.[57-59] In individuals with chronic hepatitis C genotype 2 
and 3, if the chronic hepatitis B requires treatment, then pegylated 
interferon alpha could be continued for 1 year or NUC therapy 
considered. There is a potential risk of HBV reactivation during 
treatment or after HCV clearance, which should be treated with 
NUCs. 
18.7 HBV/HIV co-infected patients
HBV/HIV co-infected patients are at greater risk of progression to 
cirrhosis and have a higher risk of HCC.[3,60-62] As immune reconstitution, 
following the initiation of antiretrovirals, can lead to potentially life-
threatening flares of hepatitis B, all HBV/HIV co-infected patients 
with a CD4 count ≤350 cells/ml should receive antiretroviral therapy 
that is also active against the HBV. Therapy should include lamivudine, 
tenofovir or tenofovir/emtricitabine, together with a third agent active 
against HIV.[63] If antiretrovirals need to be changed because of HIV 
resistance or drug toxicity, then tenofovir and lamivudine or tenofovir/
emtricitabine should be continued together with the new antiretroviral 
drugs. Pegylated interferon is only considered in patients who have a 
CD4 count >500 cells/ml.[16]
18.8 Severe acute hepatitis B
Antiviral therapy is not necessary for uncomplicated symptomatic 
acute hepatitis B, as >95% of immunocompetent adults will 
spontaneously clear HBV. It has been reported that lamivudine 
improves survival in patients with severe or fulminant hepatitis 
B.[30,32] Treatment of these patients is also justified, as reducing HBV 
DNA to undetectable levels lowers the risk of recurrent hepatitis B, 
should they require liver transplantation. NUC therapy has been 
recommended in patients with prolonged, severe acute hepatitis B 
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(elevated INR >1.5 and marked jaundice persisting for longer than 4 
weeks).[11] It is also recommended that elderly or immunosuppressed 
patients and those co-infected with HCV should be treated, as they 
are more likely to have a subfulminant/fulminant course.
Lamivudine can be used in the acute setting as treatment is 
usually of short duration, unless liver transplantation is required. 
Entecavir can also be used. However, tenofovir has the potential for 
nephrotoxicity and should be used with caution when the patient’s 
clinical condition is unstable in the acute setting. NUC therapy 
should be continued for at least 3 months after seroconversion 
to anti-HBs, or 12 months after anti-HBe seroconversion 
without HBsAg loss, or indefinitely if the patient undergoes liver 
transplantation. 
Interferon-based therapy is contraindicated because of the risk 
of acute liver failure.
19. Prevention of hepatitis B
19.1  Prevention of transmission of hepatitis B from 
individuals with chronic HBV infection
Patients with chronic hepatitis B should receive counselling 
regarding cofactors likely to accelerate disease progression (such 
as alcohol), the risk and modes of transmission and the need for 
long-term follow-up.
The following is advised:
• Abstinence. Significant ethanol intake (>20 g/day in women 
and >30 g/day in men) is associated with an increased risk of 
development of cirrhosis.[64,65]
• Household members and sexual partners are at increased risk 
of HBV infection and should be vaccinated if they are HBsAg, 
anti-HBs and IgG anti-HBc negative.
• Individuals who are HBsAg positive should: 
• Use barrier protection during sexual intercourse if the partner 
is neither immune nor has been vaccinated 
• Not share razors or toothbrushes 
• Not donate blood, organs or sperm
• Follow standard universal precautions with open cuts or bleeding
• Inform their dentist of their HBV status. 
19.2 Post-exposure prophylaxis
19.2.1 Needlestick injury/sexual exposure/mucosal or percutaneous 
(bite) exposure
• Wounds should be washed with soap and water, and mucous 
membranes flushed with water.
• Source individual should be screened for HBsAg, HIV and 
HCV Ab.
• Check HBsAg, anti-HBs and IgG anti-HBc in the exposed 
individual, to assess whether the individual is infected, immune 
or non-immune to hepatitis B.
• If source individual is HBsAg positive or status is unknown, give 
HBIG (0.06 ml/kg or 500 IU) intramuscularly and commence 
active vaccination (0, 1 and 2 months) if exposed individual 
is non-immune. HBIG and vaccine to be given at different 
injection sites. Repeat HBIG at 1 month, if the contact is HBeAg 
positive, has high HBV DNA levels or if this information is not 
known. If the exposed individual is a known non-responder 
to HBV vaccination, then 2 doses of HBIG should be given 1 
month apart.
• Anti-HBs titres should be measured 1 - 2 months after 
vaccination.
19.2.2 Babies born to HBsAg-positive mothers
• HBIG (200 IU IM) and hepatitis B vaccine should be administered 
at different sites within 12 hours of delivery.[66] The vaccine and 
immunoglobulin must be given at different injection sites. 
Thereafter, the same immunisation schedule is followed as for 
other infants, with additional doses of HBV vaccine given at 6, 
10 and 14 weeks according to the South African EPI.
• Ideally the active and passive immunisation should be given 
within 24 hours of delivery (preferably <12 hours), but 
immunisation is probably protective if administered up to 72 
hours after delivery.
• The combination of active and passive immunisation is 95% 
effective in preventing perinatal transmission, but this is probably 
lower if the maternal HBV DNA levels are >2 x 107 IU/ml.
• If the mother is HBeAg positive or has high HBV DNA levels, 
HBIG can be repeated at 1 month.
• HBsAg and anti-HBs titres should be measured at 9 - 18 months 
of age. If anti-HBs titres are <10 mIU/ml, a second course 
of vaccination should be given. If HBsAg positive, the infant 
should be referred for further monitoring.
19.2.3 Prevention of recurrent hepatitis B after liver transplantation
Pre-transplant therapy with a potent NUC and a high genetic 
barrier to resistance is recommended for all HBsAg-positive 
patients undergoing liver transplantation, in an attempt to achieve 
an undetectable HBV DNA level before transplantation.[67-70] Post 
transplantation, an NUC must be used in combination with HBIG. 
To date, lamivudine and/or adefovir have been used in combination 
with HBIG and this has reduced the risk of recurrent hepatitis B to 
<10%. However, the more potent NUCs with lower risks of resistance 
(entecavir, tenofovir) or combination NUC therapy (lamivudine 
and tenofir or tenofovir/emtricitabine) should now be used together 
with HBIG. Lifelong antiviral therapy to prevent recurrent hepatitis 
B is required. The dosage, mode of administration (IVI or IMI) and 
duration of HBIG therapy in combination with potent NUCs are not 
yet established.
19.2.4 Prevention of hepatitis B following transplantation of non-
hepatic organs from donors who are HBsAg negative and IgG 
HBcAb positive 
• Risk of infection is low, ranging from 0 to 13%[71]
• Should ideally be given to an HBV-immune recipient
• If the recipient is HBV seronegative, antiviral therapy should be 
given to prevent de novo hepatitis B, particularly if the donor is 
HBV DNA positive
• Optimal duration of prophylactic treatment is not known, but 
6 - 12 months might be sufficient.
19.2.5 Prevention of hepatitis B following the transplantation 
of livers from donors who are HBsAg negative and IgG HBcAb 
positive 
• Risk of de novo hepatitis B infection is as high as 75%[72-74] 
depending on the HBV immune status of the recipient. The 
risk is particularly high in endemic countries such as SA, where 
these donors often have occult hepatitis B. 
• Lifelong antiviral therapy is recommended.[75]
• In the setting of potent NUCs with a high barrier to resistance, 
the need for, optimal dosage and duration of HBIG prophylaxis 
is currently not known.
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• At present, we recommend a combination of HBIG and antiviral 
therapy (tenofovir +/- lamivudine). 
19.3 Vaccination
Since April 1995, HBV vaccination has been part of the South African 
EPI and is given at 6, 10 and 14 weeks of age. If a dosage is missed, 
then catch-up doses are given 1 month apart to complete the schedule. 
Vaccination is recommended in the following individuals:
i. All infants, through the EPI 
ii.  Infants and adolescents not previously vaccinated should receive 
catch-up vaccination
iii.  Individuals at increased risk of HBV infection as a result of 
percutaneous or mucosal exposure to blood or blood products, 
as well as those at risk of more severe infection. These include:
• Healthcare personnel including student healthcare workers 
and domestic workers in healthcare facilities 
• Laboratory staff working with clinical specimens
• Policemen, firemen and members of the armed forces
• Personnel and residents of the correctional services and 
institutions/schools for the mentally handicapped
• All personnel and children attending crèches and preschools
• Morticians and embalmers
• IV drug users
• Men who have sex with men 
• Patients in haemodialysis or oncology units
• Transplant candidates before transplantation
• Household contacts and sexual partners of HBsAg-positive 
individuals
• Individuals receiving frequent blood or blood product 
transfusions 
• Individuals with HIV or chronic hepatitis C.
It is important to remember that hepatitis B is endemic in 
SA. Thus all South Africans are potentially at risk of contracting 
hepatitis B infection and should consider vaccination.
HBV vaccines are either recombinant or plasma derived. Both 
formulations are safe and do not transmit hepatitis B or HIV. Plasma-
derived vaccines are thought to be more immunogenic. Dosing 
schedules depend on the type of vaccine, age of administration, 
need for rapid immunisation and previous non-response to HBV 
vaccination. Combined hepatitis A and B vaccines are also available. 
Approximately 10% of healthy adults do not mount an anti-HBs 
response (≥10 mIU/ml) to the primary immunisation schedule and 
should receive a repeat 3-dose (1 month apart) vaccination. This 
gives rise to protective antibody levels in 44 - 100% of individuals. 
Individuals who do not develop protective HBs antibody levels 1 - 2 
months after revaccination can be considered for repeat vaccination 
(0, 1 and 2 months with a 6-month booster) with double the standard 
dosage of vaccine. 
20.  Screening for HCC[5,9,76]
The aim of HCC screening is to detect tumours smaller than 3 cm and 
preferably less than 2 cm in order to offer curative therapy. Cirrhotics 
have the highest risk of HCC. However, in SA, HBV infection is 
frequently acquired in childhood, with the consequent risk of occult 
infection and HBV gene incorporation into the hepatocyte genome, 
and HCC can therefore develop in a non-cirrhotic liver.
HCC surveillance with ultrasound of the liver and serum 
α-fetoprotein is recommended every 6 - 12 months for:
• Africans older than 20 years
• Asian males ≥40 years and Asian females ≥50 years
• All cirrhotic patients regardless of age
• Individuals with a family history of HCC, regardless of age
• Any individual with HBV/HIV co-infection
• Individuals with HBeAg-positive or HBeAg-negative disease
• Any carrier aged >40 years with persistent or intermittent ALT 
elevation and/or a high HBV DNA level >2 000 IU/ml
• Any carrier who has other risk factors for HCC.
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